[go: up one dir, main page]

DK2181190T3 - Modificerede lecithin-kolesterol-acyltransferase-enzymer - Google Patents

Modificerede lecithin-kolesterol-acyltransferase-enzymer

Info

Publication number
DK2181190T3
DK2181190T3 DK08796592T DK08796592T DK2181190T3 DK 2181190 T3 DK2181190 T3 DK 2181190T3 DK 08796592 T DK08796592 T DK 08796592T DK 08796592 T DK08796592 T DK 08796592T DK 2181190 T3 DK2181190 T3 DK 2181190T3
Authority
DK
Denmark
Prior art keywords
cholesterol acyltransferase
modified lecithin
acyltransferase enzymes
enzymes
lecithin
Prior art date
Application number
DK08796592T
Other languages
English (en)
Inventor
Mingyue Zhou
Thomas Boone
David Park Meininger
Margrit Schwartz
Bei Shan
Wenyan Shen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK2181190T3 publication Critical patent/DK2181190T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01043—Phosphatidylcholine-sterol O-acyltransferase (2.3.1.43), i.e. lecithin-cholesterol acyltransferase or LCAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
DK08796592T 2007-07-26 2008-07-25 Modificerede lecithin-kolesterol-acyltransferase-enzymer DK2181190T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95200707P 2007-07-26 2007-07-26
PCT/US2008/071119 WO2009015314A2 (en) 2007-07-26 2008-07-25 Modified lecithin-cholesterol acyltransferase enzymes

Publications (1)

Publication Number Publication Date
DK2181190T3 true DK2181190T3 (da) 2014-03-31

Family

ID=39864722

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08796592T DK2181190T3 (da) 2007-07-26 2008-07-25 Modificerede lecithin-kolesterol-acyltransferase-enzymer
DK12003811T DK2489731T3 (da) 2007-07-26 2008-07-25 Modificerede lecithin-kolesterol-acyltransferase-enzymer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12003811T DK2489731T3 (da) 2007-07-26 2008-07-25 Modificerede lecithin-kolesterol-acyltransferase-enzymer

Country Status (25)

Country Link
US (3) US8168416B2 (da)
EP (4) EP2489730B1 (da)
JP (5) JP5643643B2 (da)
KR (1) KR20100040937A (da)
CN (1) CN101855344B (da)
AU (1) AU2008279065B2 (da)
BR (1) BRPI0814310A2 (da)
CA (1) CA2694590A1 (da)
CR (1) CR11272A (da)
CY (2) CY1114857T1 (da)
DK (2) DK2181190T3 (da)
EA (1) EA201070187A1 (da)
ES (3) ES2513716T3 (da)
HR (1) HRP20140315T1 (da)
IL (1) IL203399A0 (da)
MX (1) MX348799B (da)
MY (1) MY159075A (da)
NZ (2) NZ582794A (da)
PL (2) PL2489731T3 (da)
PT (2) PT2489731E (da)
RS (1) RS53237B (da)
SG (1) SG186016A1 (da)
SI (2) SI2489731T1 (da)
UA (1) UA103304C2 (da)
WO (1) WO2009015314A2 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2181190T3 (da) * 2007-07-26 2014-03-31 Amgen Inc Modificerede lecithin-kolesterol-acyltransferase-enzymer
US8492108B2 (en) * 2009-06-12 2013-07-23 Bruce J. Auerbach Methods of treating anemia and red blood cell dysfunction with lecithin cholesterol acyltransferase
JP6174995B2 (ja) * 2010-05-06 2017-08-02 メディミューン，エルエルシー コレステリルエステルのステロイド産生組織への送達
EP2701732B1 (en) * 2011-02-25 2017-08-30 University Of Patras Lecithin:cholesterol acyltransferase (lcat) and its role in nonalcoholic fatty liver disease (nafld)
RU2639521C2 (ru) 2011-05-05 2017-12-21 ВЕЛЛСТАТ ИММЬЮНОТЕРАПЬЮТИКС, ЭлЭлСи Аналоги фактора комплемента в и их применения
MX368200B (es) 2011-12-08 2019-09-24 Amgen Inc Proteinas de union al antigeno lecitin colesterol aciltransferasas humanas agonistas y su uso en terapia.
WO2016022547A1 (en) * 2014-08-06 2016-02-11 Indiana University Research And Technology Corporation Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis
WO2016123569A2 (en) * 2015-01-29 2016-08-04 Plantvax, Inc. Highly expressed protective plant-derived broadly neutralizing hiv monoclonal antibodies for use in passive immunotherapy
US11883470B2 (en) 2016-07-25 2024-01-30 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
KR20200085292A (ko) * 2017-11-07 2020-07-14 알파코어 파마 엘엘씨 심장 질병, 심혈관 질병 및 관련 질환 및 증상을 치료하고 그로부터 보호하는 방법
JP7460540B2 (ja) * 2018-05-22 2024-04-02 ディーエスエム アイピー アセッツ ビー．ブイ． 修飾ステロールアシルトランスフェラーゼ
US11612619B2 (en) 2018-11-01 2023-03-28 National Institute Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Compostions and methods for enabling cholesterol catabolism in human cells
WO2021174100A1 (en) 2020-02-28 2021-09-02 Repair Biotechnologies, Inc. Targeted expression of microbial cholesterol catalysis genes reduces excess lipid

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JPS63167409A (ja) 1986-12-27 1988-07-11 Yamaha Corp 磁気記録体
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
DE3856378T2 (de) 1987-09-04 2000-05-11 Beecham Group P.L.C., Brentford Substituierte Thiazolidindionderivate
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
HU217629B (hu) 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
CA2118130A1 (en) 1992-04-14 1993-10-28 Jean M. J. Frechet Dendritic based macromolecules and method of production
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
DE69324504T2 (de) 1993-01-19 1999-08-26 Warner-Lambert Co. Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IL128864A (en) 1995-07-17 2007-10-31 Warner Lambert Co Atorostatin II form crystals and its hydrates, methods of preparation and pharmaceutical preparations containing it
AU728257B2 (en) * 1995-11-09 2001-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The The use of lecithin-cholesterol acyltransferase (LCAT) in the treatment of atherosclerosis
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
CA2284832A1 (en) * 1997-04-11 1998-10-22 Takeda Chemical Industries, Ltd. Proteins having lecithin-cholesterol acyltransferase-like activity, their production and use
ES2206868T3 (es) 1998-07-15 2004-05-16 Merck Sante Comprimidos que comprenden una combinacion de metformin glibenclamida.
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2001005943A2 (en) 1999-07-14 2001-01-25 Betagene, Inc. Lcat recombinant cell line compositions and methods
ATE540681T1 (de) 2006-06-26 2012-01-15 Amgen Inc Verfahren zur behandlung von atherosklerose
DK2181190T3 (da) * 2007-07-26 2014-03-31 Amgen Inc Modificerede lecithin-kolesterol-acyltransferase-enzymer

Also Published As

Publication number Publication date
MY159075A (en) 2016-12-15
WO2009015314A3 (en) 2009-03-12
BRPI0814310A2 (pt) 2015-01-06
JP2020058366A (ja) 2020-04-16
SI2181190T1 (sl) 2014-04-30
JP2018161134A (ja) 2018-10-18
EP2489730A1 (en) 2012-08-22
CN101855344B (zh) 2015-12-09
CA2694590A1 (en) 2009-01-29
EP2181190B1 (en) 2014-01-08
IL203399A0 (en) 2011-07-31
KR20100040937A (ko) 2010-04-21
CN101855344A (zh) 2010-10-06
JP5643643B2 (ja) 2014-12-17
US20090081182A1 (en) 2009-03-26
JP6033258B2 (ja) 2016-11-30
UA103304C2 (ru) 2013-10-10
EP2181190A2 (en) 2010-05-05
CR11272A (es) 2010-05-26
EP2489731A1 (en) 2012-08-22
EP2522721A3 (en) 2013-01-23
RS53237B (sr) 2014-08-29
MX348799B (es) 2017-06-29
US8168416B2 (en) 2012-05-01
CY1114857T1 (el) 2016-12-14
WO2009015314A2 (en) 2009-01-29
PT2181190E (pt) 2014-02-24
EP2522721A2 (en) 2012-11-14
EA201070187A1 (ru) 2010-08-30
HRP20140315T1 (hr) 2014-05-09
US20140287479A1 (en) 2014-09-25
AU2008279065A1 (en) 2009-01-29
JP2010534479A (ja) 2010-11-11
PL2489731T3 (pl) 2015-01-30
HK1138039A1 (en) 2010-08-13
ES2513716T3 (es) 2014-10-27
NZ582794A (en) 2012-09-28
CY1115573T1 (el) 2017-01-04
JP2014198047A (ja) 2014-10-23
PL2181190T3 (pl) 2014-06-30
NZ597885A (en) 2013-08-30
DK2489731T3 (da) 2014-11-17
AU2008279065B2 (en) 2013-12-12
SG186016A1 (en) 2012-12-28
US8703926B1 (en) 2014-04-22
SI2489731T1 (sl) 2014-12-31
ES2559353T3 (es) 2016-02-11
EP2489730B1 (en) 2015-12-30
EP2522721B1 (en) 2016-05-04
ES2449483T3 (es) 2014-03-19
JP2016182136A (ja) 2016-10-20
PT2489731E (pt) 2014-09-15
EP2489731B1 (en) 2014-08-27
US9006408B2 (en) 2015-04-14

Similar Documents

Publication Publication Date Title
DK2181190T3 (da) Modificerede lecithin-kolesterol-acyltransferase-enzymer
BRPI0808014A2 (pt) Variantes de transglutaminase com especificidade melhorada
BRPI0908237A2 (pt) Pequenos grânulos contendo enzima
DK2155852T3 (da) Forbedret fleksibel bioreaktor
EP2518147A4 (en) DIACYLGLYCEROLACYLTRANSFERASEGEN AND ITS USE
PL2634242T3 (pl) Ulepszony sposób hodowli komórek
DK2119781T3 (da) Glyceroglycolipidlipase
EP2404999A4 (en) HEAT-TOLERANT TRANSGLUTAMINASE FROM ACTINOMYCES
DE112008002581A5 (de) Antriebsstrang
EP2169055A4 (en) NEW LYSOPHOSPHATIDATE ACYLTRANSFERASE GEN
BRPI0810384A2 (pt) Terapia enzimática anticâncer
DK2511369T3 (da) Proteasestabile cellevægslyserende enzymer
EP2192402A4 (en) Enzyme electrode
GB0804721D0 (en) Enzyme
GB0818328D0 (en) Novel enzyme
GB0803628D0 (en) Enzyme
BRPI0917522A2 (pt) Protetores de cultura
GB0804722D0 (en) Enzyme
DK2042015T3 (da) Centrifugalspreder
BRPI0818162A2 (pt) Métodos enzimáticos e enzimas
BRPI0906321A2 (pt) "multienzima"
DE112007003032A5 (de) Antriebsstrang
FI20070190A0 (fi) Bioreaktori
GB0711245D0 (en) Enzyme
GB0713609D0 (en) Enzyme